Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
Australia
0
South Africa
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Cyclobenzaprine
2. Flexeril
3. Lisseril
1. 6202-23-9
2. Cyclobenzaprine Hcl
3. Flexeril
4. Flexiban
5. Amrix
6. Lisseril
7. 3-(5h-dibenzo[a,d][7]annulen-5-ylidene)-n,n-dimethylpropan-1-amine Hydrochloride
8. Cyclobenzaprine (hydrochloride)
9. Mk 130 Hydrochloride
10. Proheptatriene Hydrochloride
11. Mk130 Hydrochloride
12. Proheptatriene Monohydrochloride
13. Tnx-102
14. Nsc-78206
15. Nsc-169900
16. Nsc-173379
17. 0ve05jys2p
18. Chebi:3997
19. 5-(3-dimethylaminopropylidene)dibenzo[a,e]cycloheptatriene Hydrochloride
20. 1-propanamine, 3-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-n,n-dimethyl-, Hydrochloride
21. N,n-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)propan-1-amine;hydrochloride
22. Cycloflex
23. Tensodox
24. Cloben
25. Cyben
26. Novo-cycloprine
27. Flexeril Hydrochloride
28. Dsstox_cid_25105
29. Dsstox_rid_80672
30. Dsstox_gsid_45105
31. Tabradol
32. Yurelax
33. Miosan
34. Mk-130 Hcl
35. Multi-relax
36. 10,11.delta.-amitriptyline Hydrochloride
37. Proheptatrien Monohydrochloride
38. Wln: L C676 Bhj B3n1&1 &gh
39. Nsc78206
40. 5h-dibenzo[a, N,n-dimethyl-, Hydrochloride
41. Nsc169900
42. Nsc173379
43. Sr-01000075761
44. Cyclobenzaprine Hydrochloride [usan]
45. Einecs 228-264-4
46. Cas-6202-23-9
47. Nsc 78206
48. Unii-0ve05jys2p
49. Nsc 169900
50. Nsc 173379
51. 10,11delta-amitriptyline Hydrochloride
52. 5h-dibenzo[a,.gamma.-propylamine, N,n-dimethyl-, Hydrochloride
53. N,d]cycloheptene-.delta.,5.gamma.-propylamine, Hydrochloride
54. Tonmya
55. 1-propanamine,d]cyclohepten-5-ylidene)-n,n-dimethyl-, Hydrochloride
56. N,d]cycloheptene-.delta.(sup5,.gamma.)-propylamine Hydrochloride
57. 5-[3-(dimethylamino)propylidene]-5h-dibenzo-[a,d]cycloheptene Hydrochloride
58. 3-(dibenzo[2,1-b:1',2'-e][7]annulen-11-ylidene)-n,n-dimethylpropan-1-amine;hydrochloride
59. Flexeril (tn)
60. Prestwick_790
61. Mfcd00079039
62. Cyclobenzaprine Hydrochloride [usan:usp]
63. Nortriptyline Impurity E
64. 5-(3-dimethylaminopropylidene)-5h-dibenzo-(a,d)cycloheptene Hydrochloride
65. N,n-dimethyl-5h-dibenzo(a,d)cycloheptene-delta(sup 5,gamma)-propylamine Hydrochloride
66. Schembl41376
67. Mls002153815
68. Mk-130 Hydrochloride
69. Spectrum1503207
70. Amy502
71. Tnx-102 Sl
72. Chembl1200636
73. Dtxsid2045105
74. Tnx-105
75. Hms1569i12
76. Hms1922i11
77. Pharmakon1600-01503207
78. Act06294
79. Bcp21781
80. Cyclobenzaprine Hydrochloride (usp)
81. Eur-1002
82. Hy-b0740
83. Tox21_110040
84. Tox21_500303
85. Ccg-39312
86. Nsc758414
87. S4283
88. 3-(5h-dibenzo(a,d)cyclohepten-5-ylidene)propyl(dimethyl)ammonium Chloride
89. Akos015906329
90. Tox21_110040_1
91. Ac-1916
92. Bcp9000565
93. Lp00303
94. Nsc-758414
95. Sb19022
96. 5h-dibenzo(a,d)cycloheptene-delta(sup 5)-gamma-propylamine, N,n-dimethyl-, Hydrochloride
97. 5h-dibenzo(a,d)cycloheptene-delta5,gamma-propylamine, N,n-dimethyl-, Hydrochloride
98. Ncgc00013841-01
99. Ncgc00013841-09
100. Ncgc00093752-01
101. Ncgc00093752-02
102. Ncgc00093752-03
103. Ncgc00093752-04
104. Ncgc00093752-05
105. Ncgc00095017-01
106. Ncgc00095017-02
107. Ncgc00095017-03
108. Ncgc00095017-04
109. Ncgc00260988-01
110. As-15745
111. Bc181325
112. Cyclobenzaprine Hydrochloride [mi]
113. Smr000326702
114. Cyclobenzaprine Hydrochloride [mart.]
115. Cyclobenzaprine Hydrochloride [vandf]
116. Eu-0100303
117. Ft-0603166
118. Sw196928-3
119. Cyclobenzaprine Hydrochloride [usp-rs]
120. Cyclobenzaprine Hydrochloride [who-dd]
121. A14255
122. C 4542
123. D00772
124. L10029
125. 202c239
126. A854881
127. Cyclobenzaprine Hydrochloride [orange Book]
128. Cyclobenzaprine Hydrochloride [usp Impurity]
129. Cyclobenzaprine Hydrochloride [usp Monograph]
130. Sr-01000075761-1
131. Sr-01000075761-6
132. W-105056
133. Q27106282
134. Cyclobenzaprine Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
135. 3-(5h-dibenzo[a,d][7]annulen-5-ylidene)-n,n-dimethylpropan-1-aminehydrochloride
136. 3-(5h-dibenzo[a,d]cyclohepten-5-ylidene)-n,n-dimethylpropan-1-amine Hydrochloride
137. Cyclobenzaprine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
138. N,n-dimethyl-5h-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine Hydrochloride
139. 3-(5h-dibenzo[a,d][7]annulen-5-ylidene)-n,n-dimethylpropan-1-amine Hydrochloride (cyclobenzaprine Hydrochloride)
140. Cyclobenzaprine Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
141. N,n-dimethyl-5h-dibenzo(a,d)cycloheptene-(sup .delta.5,.gamma.)-propylamine Hydrochloride
Molecular Weight | 311.8 g/mol |
---|---|
Molecular Formula | C20H22ClN |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 3 |
Exact Mass | 311.1440774 g/mol |
Monoisotopic Mass | 311.1440774 g/mol |
Topological Polar Surface Area | 3.2 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 365 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Amrix |
PubMed Health | Cyclobenzaprine (By mouth) |
Drug Classes | Skeletal Muscle Relaxant, Centrally Acting |
Drug Label | AMRIX (Cyclobenzaprine Hydrochloride Extended-Release Capsules) is a skeletal muscle relaxant which relieves muscle spasm of local origin without interfering with muscle function. The active ingredient in AMRIX extended-release capsules is cycloben... |
Active Ingredient | Cyclobenzaprine hydrochloride |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 30mg; 15mg |
Market Status | Prescription |
Company | Ivax Intl |
2 of 4 | |
---|---|
Drug Name | Cyclobenzaprine hydrochloride |
Drug Label | Cyclobenzaprine hydrochloride is a white, crystalline tricyclic amine salt. It has a melting point of 217C, and a pKa of 8.47 at 25C. It is freely soluble in water and alcohol, sparingly soluble in isopropanol, and insoluble in hydrocarbon solven... |
Active Ingredient | Cyclobenzaprine hydrochloride |
Dosage Form | Tablet; Capsule, extended release |
Route | oral; Oral |
Strength | 5mg; 7.5mg; 30mg; 10mg; 15mg |
Market Status | Tentative Approval; Prescription |
Company | Vintage Pharms; Twi Pharms; Ranbaxy; Mylan Pharms; Jubilant Cadista; Mutual Pharm; Kvk Tech; Actavis Labs Fl; Orit Labs; Aurobindo Pharma; Prosam Labs; Pliva; Invagen Pharms; Par Pharm |
3 of 4 | |
---|---|
Drug Name | Amrix |
PubMed Health | Cyclobenzaprine (By mouth) |
Drug Classes | Skeletal Muscle Relaxant, Centrally Acting |
Drug Label | AMRIX (Cyclobenzaprine Hydrochloride Extended-Release Capsules) is a skeletal muscle relaxant which relieves muscle spasm of local origin without interfering with muscle function. The active ingredient in AMRIX extended-release capsules is cycloben... |
Active Ingredient | Cyclobenzaprine hydrochloride |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 30mg; 15mg |
Market Status | Prescription |
Company | Ivax Intl |
4 of 4 | |
---|---|
Drug Name | Cyclobenzaprine hydrochloride |
Drug Label | Cyclobenzaprine hydrochloride is a white, crystalline tricyclic amine salt. It has a melting point of 217C, and a pKa of 8.47 at 25C. It is freely soluble in water and alcohol, sparingly soluble in isopropanol, and insoluble in hydrocarbon solven... |
Active Ingredient | Cyclobenzaprine hydrochloride |
Dosage Form | Tablet; Capsule, extended release |
Route | oral; Oral |
Strength | 5mg; 7.5mg; 30mg; 10mg; 15mg |
Market Status | Tentative Approval; Prescription |
Company | Vintage Pharms; Twi Pharms; Ranbaxy; Mylan Pharms; Jubilant Cadista; Mutual Pharm; Kvk Tech; Actavis Labs Fl; Orit Labs; Aurobindo Pharma; Prosam Labs; Pliva; Invagen Pharms; Par Pharm |
Antidepressive Agents, Tricyclic
Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)
Muscle Relaxants, Central
A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)
Tranquilizing Agents
A traditional grouping of drugs said to have a soothing or calming effect on mood, thought, or behavior. Included here are the ANTI-ANXIETY AGENTS (minor tranquilizers), ANTIMANIC AGENTS, and the ANTIPSYCHOTIC AGENTS (major tranquilizers). These drugs act by different mechanisms and are used for different therapeutic purposes. (See all compounds classified as Tranquilizing Agents.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-06-23
Pay. Date : 2015-05-04
DMF Number : 5827
Submission : 1985-05-10
Status : Active
Type : II
NDC Package Code : 53296-0003
Start Marketing Date : 2010-03-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (75kg/75kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-04-08
Pay. Date : 2020-03-04
DMF Number : 33147
Submission : 2018-09-26
Status : Active
Type : II
Date of Issue : 2021-08-06
Valid Till : 2022-07-28
Written Confirmation Number : WC-0445A4
Address of the Firm :
NDC Package Code : 71554-116
Start Marketing Date : 2020-05-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29955
Submission : 2015-11-09
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-02-20
Pay. Date : 2014-02-13
DMF Number : 21392
Submission : 2008-03-05
Status : Active
Type : II
Date of Issue : 2022-07-04
Valid Till : 2025-07-03
Written Confirmation Number : WC-0040
Address of the Firm :
NDC Package Code : 65977-0030
Start Marketing Date : 1982-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34654
Submission : 2020-03-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24719
Submission : 2011-03-26
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8115
Submission : 1989-06-20
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9510
Submission : 1992-01-20
Status : Inactive
Type : II
Registration Number : 306MF10003
Registrant's Address : Via Bissone, 5, 20021-Baranzate, Milano, Italy
Initial Date of Registration : 2024-01-11
Latest Date of Registration : 2024-01-11
Cyclobenzaprine Hydrochloride (USP)
Date of Issue : 2022-07-04
Valid Till : 2025-07-03
Written Confirmation Number : WC-0040
Address of the Firm : Unit-I, Survey No.213, 214 & 255, Bonthapally Village, Jinnaram Mandal, Medak ...
Date of Issue : 2021-08-06
Valid Till : 2022-07-28
Written Confirmation Number : WC-0445A4
Address of the Firm : Plot No. IP No. 27-29, Parts of Sy. Nos 18, 273, 274 & 313, KIADB Industrial Are...
Cyclobenzaprine Hydrochloride USP
Date of Issue : 2019-07-22
Valid Till : 2022-07-22
Written Confirmation Number : WC-0139
Address of the Firm : # 15, KHB Industrial Area, Yelahanka, Bangalore-560 064
Cyclobenzaprine Hydrochloride USP
Date of Issue : 2022-06-14
Valid Till : 2025-07-04
Written Confirmation Number : WC-0070
Address of the Firm : Unit-1, Plot No. 37A, 38, 39 A&B, Phase-1, IDA, Jeedimetla, Hyderabad-500 055, T...
Cyclobenzaprine Hydrochloride USP
Date of Issue : 2022-06-14
Valid Till : 2025-07-04
Written Confirmation Number : WC-0070
Address of the Firm : Unit-1, Plot No. 37A, 38, 39 A&B, Phase-1, IDA, Jeedimetla, Hyderabad-500 055, T...
Cyclobenzaprine Hydrochloride (USP/1H)
Date of Issue : 2022-06-22
Valid Till : 2025-07-28
Written Confirmation Number : WC-0117
Address of the Firm : Unit-VII, Plot No. 14, 99, &100, IDA, Pashamylaram, Phase-II, Patancheru,Sangare...
Cyclobenzaprine Hydrochloride USP
Date of Issue : 2019-08-13
Valid Till : 2022-07-28
Written Confirmation Number : WC-0117A2
Address of the Firm : Unit-VII, Plot No. 14, 99, &100, IDA, Pashamylaram, Phase-II, Patancheru, Medak ...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Cyclobenzaprine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cyclobenzaprine, including repackagers and relabelers. The FDA regulates Cyclobenzaprine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cyclobenzaprine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cyclobenzaprine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cyclobenzaprine supplier is an individual or a company that provides Cyclobenzaprine active pharmaceutical ingredient (API) or Cyclobenzaprine finished formulations upon request. The Cyclobenzaprine suppliers may include Cyclobenzaprine API manufacturers, exporters, distributors and traders.
click here to find a list of Cyclobenzaprine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cyclobenzaprine DMF (Drug Master File) is a document detailing the whole manufacturing process of Cyclobenzaprine active pharmaceutical ingredient (API) in detail. Different forms of Cyclobenzaprine DMFs exist exist since differing nations have different regulations, such as Cyclobenzaprine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cyclobenzaprine DMF submitted to regulatory agencies in the US is known as a USDMF. Cyclobenzaprine USDMF includes data on Cyclobenzaprine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cyclobenzaprine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cyclobenzaprine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cyclobenzaprine Drug Master File in Japan (Cyclobenzaprine JDMF) empowers Cyclobenzaprine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cyclobenzaprine JDMF during the approval evaluation for pharmaceutical products. At the time of Cyclobenzaprine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cyclobenzaprine suppliers with JDMF on PharmaCompass.
A Cyclobenzaprine written confirmation (Cyclobenzaprine WC) is an official document issued by a regulatory agency to a Cyclobenzaprine manufacturer, verifying that the manufacturing facility of a Cyclobenzaprine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cyclobenzaprine APIs or Cyclobenzaprine finished pharmaceutical products to another nation, regulatory agencies frequently require a Cyclobenzaprine WC (written confirmation) as part of the regulatory process.
click here to find a list of Cyclobenzaprine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cyclobenzaprine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cyclobenzaprine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cyclobenzaprine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cyclobenzaprine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cyclobenzaprine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cyclobenzaprine suppliers with NDC on PharmaCompass.
Cyclobenzaprine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cyclobenzaprine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cyclobenzaprine GMP manufacturer or Cyclobenzaprine GMP API supplier for your needs.
A Cyclobenzaprine CoA (Certificate of Analysis) is a formal document that attests to Cyclobenzaprine's compliance with Cyclobenzaprine specifications and serves as a tool for batch-level quality control.
Cyclobenzaprine CoA mostly includes findings from lab analyses of a specific batch. For each Cyclobenzaprine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cyclobenzaprine may be tested according to a variety of international standards, such as European Pharmacopoeia (Cyclobenzaprine EP), Cyclobenzaprine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cyclobenzaprine USP).
LOOKING FOR A SUPPLIER?